The new product incorporates a change in the salt from perindopril tert-butylamine to perindopril arginine.
The formulation change was made to harmonise global manufacturing and the new products will benefit from a 50 per cent increase in shelf life, according to the manufacturer. New stock is already available and will be replacing existing products. There is no active recall of Coversyl and Coversyl Plus.
Perindopril arginine is not dose equivalent to the existing perindopril tert-butylamine products and prescribers will need to convert the dose as follows:
- Perindopril tert-butylamine 2mg = perindopril arginine 2.5mg
- Perindopril tert-butylamine 4mg = perindopril arginine 5mg
- Perindopril tert-butylamine 8mg = perindopril arginine 10mg
Patients currently receiving Coversyl as a branded prescription will need to have their prescription altered. They can either be prescribed perindopril tert-butylamine as a generic medicine, and are therefore maintained on the same dose and formulation. Alternatively, patients can be switched to perindopril arginine according to the dose conversion above.
Those receiving Coversyl Plus (perindopril 4mg + indapamide 1.25mg) can also be prescribed generically or switched to Coversyl Arginine Plus.
There is no need to alter prescriptions for patients currently receiving generic versions of perindopril.
Further information: Servier